Clinical utility of radiolabeled monoclonal antibodies in prostate cancer

Clinical Genitourinary Cancer

Volumn 4, Issue 4, 2006, Pages 249-256

  David, Kevin A ^a   Milowsky, Matthew I ^a   Kostakoglu, Lale ^a   Vallabhajosula, Shankar ^a   Goldsmith, Stanley J ^a   Nanus, David M ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Indium 111; J591; Lutetium 177; Prostate stem cell antigen; Prostate specific antigen; Prostate specific membrane antigen; Prostatic acid phosphatase; Yttrium 90

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CETUXIMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRAMUSTINE; GLYCOPROTEIN; INDIUM 111; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3C5; MONOCLONAL ANTIBODY AGS PSCA; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY E99; MONOCLONAL ANTIBODY IG8; MONOCLONAL ANTIBODY J533; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY M170; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROVENGE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; YTTRIUM 90;

ABSENCE OF SIDE EFFECTS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING; DRUG HALF LIFE; DRUG INHIBITION; DRUG TARGETING; DRUG UTILIZATION; HEMATOLOGIC DISEASE; HUMAN; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 33646867242     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.003     Document Type: Review

References (65)

1. What are the key statistics about prostate cancer? American Cancer Socitey [Web site]. Available at: http://www.cancer.org/docroot/ cri_2_4_1x_what_are _the_key_statistics_for_prostate_cancer_36.asp. Accessed February 16, 2006.
2. Griffiths K, Eaton CL, Harper ME, et al. Hormonal treatment of advanced disease: some newer aspects. Semin Oncol 1994; 21:672-687.
3. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764.
4. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17:2506-2513.
5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004; 351:1513-1520.
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351:1502-1512.
7. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302.
8. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001; 344:783-792.
10. Cunningham D, Humbler Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351:337-345.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350:2335-2342.
12. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperarive Oncology Group (ECOG) trial - E4599. J Clin Oncol 2005; 23(16 suppl):2s (Abstract #4).
13. Bander NH, Nanus DM, Milowsky MI, et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30:667-676.
14. Slovin SF, Kelly WK, Cohen R, et al. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): results of a phase IB/IIA study. ProcAm Soc Clin Oncol 1997; 16:311 (Abstract #1108).
15. Lara PN Jr, Chee KG, Longmate J, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and phase II trial. Cancer 2004; 100:2125-2131.
16. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22:393 (Abstract #1578).
17. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-3903.
18. Small EJ, Schellhammer PF, Higano C, et al. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final survival data from a phase 3 randomized placebo-controlled trial. J Clin Oncol 2005; 23(16 suppl):378s (Abstract #4500).
19. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:2122-2132.
20. DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med (epub). 2006; 4:1.
21. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22:2522-2531.
22. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591-4601.
23. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001; 98:2658-2663.
24. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19:1288-1296.
25. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62:2546-2553.
26. Jakobovits A, Gudas JM, Morrison K, et al. Therapeutic potential of AGS-PSCA: a fully human monoclonal antibody to prostatestem cell antigen (PSCA) for the treatment of prostate cancer. J Clin Oncol 2005; 23(16 suppl 1):433s (Abstract #4722).
27. Cohen DW, Simak R, Fair WR, et al. Expression of transforming growth factor-alpha and the epidetmal growth factor receptor in human prostate tissues. J Urol 1994; 152:2120-2124.
28. Ratan HL, Gescher A, Steward WP, et al. ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 2003; 92:890-895.
29. Ross JS, Gray KE, Webb IJ, et al. Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev 2005; 24:521-537.
30. Foster CS, Gosden CM, Ke Y. HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol 2003; 34:635-668.
31. Signoretti S, Montironi R, Manola J, et al. HER-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92:1918-1925.
32. Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002; 94:980-986.
33. Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54:1807-1811.
34. Silvet DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81-85.
35. Trover JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62:552-558.
36. Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000; 43:150-157.
37. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629-3634.
38. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59:3192-3198.
39. Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999; 5:2674-2681.
40. Milowsky MI, Rosmarin AS, Cobham MV, et al. Anti-PSMA mAb huJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2002; 21:8a (Abstract #29).
41. O'Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998; 1443:113-127.
42. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2:1445-1451.
43. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A 1996; 93:749-753.
44. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82:2256-2261.
45. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48:326-334.
46. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58:4055-4060.
47. Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003; 14:4835-4845.
48. Trover JK, Feng Q, Beckett ML, et al. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995; 1:29-37.
49. Kahn D, Williams RD, Manyak MJ, et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998; 159:2041-2046.
50. Kahn D, Williams RD, Haseman MK, et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiothetapy after failed radical prostatectomy. J Clin Oncol 1998; 16:284-289.
51. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998; 23:672-677.
52. Wynant GE, Murphy GP, Horoszewicz JS, et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991; 18:229-241.
53. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998; 83:739-747.
54. Kahn D, Austin JC, Maguire RT, et al. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm 1999; 14:99-111.
55. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monclonal antibody Hu-J591 therapy: targeting of prostate specific membrane antigen. J Urol 2003; 170:S84-S89.
56. Hamilton A, King S, Liu H, et al. A novel humanised antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res 1998; 39:440.
57. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005; 11:7454-7561.
58. O'Donnell RT, DeNardo SJ, Yuan A, et al. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res 2001; 7:1561-1568.
59. McEwan AJ, MacLean GD, Hooper HR, et al. MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with 99Tcm and with 111In. Nucl Med Commun 1992; 13:11-19.
60. Howell LP, DeNardo SJ, Levy NB, et al. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 1995; 10:129-135.
61. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35:1017-1022.
62. Slovin SF, Scher HI, Divgi CR, et al. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643-651.
63. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
64. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res 2005; 11:7195s-7200s.
65. Richman CM, DeNardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005; 11:5920-5927.